VXA-GI.1.NN

VXA-GI.1.NN is an oral vaccine candidate developed for the prevention of noroviral gastroenteritis caused by norovirus genogroup GI.1 (Norwalk virus). It consists of a non-replicating, E1/E3-deleted recombinant adenovirus serotype 5 vector encoding the full-length VP1 gene (major capsid protein) from Norwalk virus, combined with a double-stranded RNA adjuvant that acts as a Toll-like receptor 3 (TLR3) agonist to enhance mucosal immune responses[2][3][5][6]. The vaccine is formulated as an enteric-coated tablet designed to bypass the stomach and release its contents in the small intestine, where it induces both systemic and mucosal immunity—including robust IgG and IgA antibody responses in serum, saliva, and nasal secretions[2][4][7]. Clinical trials have shown that VXA-GI.1.NN is safe and well tolerated in adults up to 80 years old, with no serious or grade 3 adverse events reported[2][4]. The vaccine has demonstrated immunogenicity by increasing VP1-specific antibody-secreting cells and reducing viral shedding after challenge[2]. It is developed by Vaxart.

Other names

Norovirus GI.1 Norwalk VP1 Vaccine